Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans

Dermatofibrosarcoma protuberans (DFSP) is a very rare soft tissue sarcoma, generally of low-grade malignancy. DFSP is locally aggressive with a high recurrence rate, but metastasis occurs rarely. To investigate the mechanism of metastasis in DFSP, we analyzed the whole exome sequencing data of serial tumor samples obtained from a patient who had a 10-year history of recurrent and metastatic DFSP. Tracking various genomic alterations, namely somatic mutations, copy number variations, and chromosomal rearrangements, we observed a dramatic change in tumor cell population during the occurrence of metastasis in this DFSP case. The new subclone that emerged in metastatic DFSP harbored a completely different set of somatic mutations and new focal amplifications, which had not been observed in the primary clone before metastasis. The COL1A1-PDGFB fusion, characteristic of DFSP, was found in all of the serial samples. Moreover, the break position on the fusion gene was identical in all samples. Based on these observations, we suggest a clonal evolution model to explain the mechanism underlying metastasis in DFSP and identified several candidate target genes responsible for metastatic DFSP by utilizing The Cancer Genome Atlas database. This is the first study to observe clonal evolution in metastatic DFSP and provide insight for a possible therapeutic strategy for imatinib-resistant or metastatic DFSP.

[1]  A. Leonardi,et al.  NF-κB Mediates the Expression of TBX15 in Cancer Cells , 2016, PloS one.

[2]  A. D. Dei Tos,et al.  Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial–Mesenchymal Transition–like Process and 22q Loss , 2016, Molecular Cancer Research.

[3]  Yoon-La Choi,et al.  Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples , 2015, PloS one.

[4]  F. Grosso,et al.  Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP) , 2015, Clinical Cancer Research.

[5]  R. Marcos,et al.  Novel antiapoptotic effect of TBX15: overexpression of TBX15 reduces apoptosis in cancer cells , 2015, Apoptosis.

[6]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[7]  Masahiko Ando,et al.  Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR , 2015, Clinical Cancer Research.

[8]  B. Giusti,et al.  EXCAVATOR: detecting copy number variants from whole-exome sequencing data , 2013, Genome Biology.

[9]  Eun Hee Lee,et al.  PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications. , 2013, Human Pathology.

[10]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[11]  Sung-Liang Yu,et al.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Pao,et al.  Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer , 2011, Molecular pharmaceutics.

[13]  Fang Fang,et al.  FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution , 2011, Bioinform..

[14]  N. Socci,et al.  Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.

[15]  M. van Glabbeke,et al.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[17]  P. Jänne,et al.  Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[18]  A. Lazar,et al.  Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. , 2008, Human pathology.

[19]  André M. Oliveira,et al.  Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans , 2006, Modern Pathology.

[20]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[21]  George Vlachos,et al.  Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. , 2006, Gynecologic oncology.

[22]  Thomas D. Wu,et al.  GMAP: a genomic mapping and alignment program for mRNA and EST sequence , 2005, Bioinform..

[23]  J. Fletcher,et al.  Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  I. Jacobs,et al.  Outcomes of surgery for dermatofibrosarcoma protuberans. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  C. Antonescu,et al.  Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans , 2002, International journal of cancer.

[26]  P. D. Dal Cin,et al.  Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. , 2001, Cancer research.

[27]  J. Kere,et al.  Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans , 2001, Cytogenetic and Genome Research.

[28]  W. Enneking,et al.  Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  T. Sjöblom,et al.  The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. , 1999, Cancer research.

[30]  G. Sozzi,et al.  Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. , 1996, Cytogenetics and cell genetics.

[31]  F. Hecht,et al.  Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. , 1995, Cancer research.

[32]  J. Fletcher,et al.  Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. , 1995, The American journal of pathology.

[33]  H. Tagami,et al.  Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34 , 1992, The British journal of dermatology.

[34]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[35]  R W Raven,et al.  The british association of surgical oncology , 1973, Annals of the Royal College of Surgeons of England.